Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations

Autores da FMUP

• João Pedro Melo Marques Pinho Ferreira

  Autor

Participantes de fora da FMUP

• Butler, J
• Anker, SD
• Filippatos, G
• Usman, MS
• Zannad, F
• Packer, MAB -

Unidades de investigação

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

[No abstract available]

Keywords

• Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; canagliflozin; dapagliflozin; empagliflozin; ertugliflozin; sodium glucose cotransporter inhibitor; sotagliflozin; cotransporter; glucose; sodium; Article; cardiovascular mortality; cardiovascular risk; chronic kidney failure; estimated glomerular filtration rate; heart failure; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; hospitalization; human; Kaplan Meier method; non insulin dependent diabetes mellitus; numbers needed to treat; risk reduction; treatment outcome; adverse event; non insulin dependent diabetes mellitus